MabionWAR:MAB -2.69%29 Market Cap is zł122.67 Mil as of Jun. 29, 2026. GuruFocus rates WAR:MAB with a GF Score™ of 29/100 and a GF Value™ of zł2.10 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,428 Biotechnology companies, Mabion ranks worse than 69.19% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Mabion's share price for the quarter that ended in Mar. 2026 was zł8.92. Mabion's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 16.16 Mil. Therefore, Mabion's market cap for the quarter that ended in Mar. 2026 was zł144.17 Mil.
Mabion's quarterly market cap
declined
from Sep. 2025 (zł138.99 Mil) to Dec. 2025 (zł112.81 Mil) but then
increased
from Dec. 2025 (zł112.81 Mil) to Mar. 2026 (zł144.17 Mil).
Mabion's annual market cap
declined
from Dec. 2023 (zł293.34 Mil) to Dec. 2024 (zł143.84 Mil) and
declined
from Dec. 2024 (zł143.84 Mil) to Dec. 2025 (zł112.81 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mabion's Enterprise Value for Today is zł141.37 Mil.
Mabion (WAR:MAB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Mabion Market Cap Related Terms
Mabion Market Cap Historical Data
* Premium members only.
The historical data trend for Mabion's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MAB vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Mabion's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabion Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabion's Market Cap distribution charts can be found below:
* The bar in red indicates where Mabion's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Mabion's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabion (WAR:MAB) has a Market Cap of zł122.67 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mabion and its competitors. According to the industry distribution chart, Mabion ranks #988 out of 1428 companies in the Biotechnology industry, placing it in the top 69.2%.
Is Mabion's Market Cap too high?
Mabion's current Market Cap is zł122.67 Mil. Based on the distribution chart, Mabion ranks #988 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mabion has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mabion's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mabion ranks #988 out of 1428 companies for Market Cap. This places Mabion in the lower half of its industry. The industry median Market Cap is 114.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mabion and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mabion's current Market Cap is zł122.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabion stock overvalued right now?
Based on GuruFocus' analysis, Mabion (WAR:MAB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł2.10, compared to a current price of zł7.59 — trading 261.4% above its estimated fair value. The current Market Cap is zł122.67 Mil. Mabion's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Mabion (WAR:MAB), the current Market Cap is zł122.67 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mabion (WAR:MAB) Overvalued in 2026?
Based on GuruFocus' analysis, Mabion stock appears to be overvalued.
The current stock price of zł7.59 is trading 261.4% above its estimated GF Value™ of zł2.10.
GuruFocus considers Mabion to be Significantly Overvalued.
Key valuation signals for WAR:MAB:
Market Cap: zł122.67 Mil
GF Value™: zł2.10 vs. price of zł7.59 (261.4% above fair value)
No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
29GF Score
Get the complete analysis for WAR:MAB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MAB has been successfully added to your 
